Discovery of potent and selective phenylalanine derived CCR3 receptor antagonists. Part 2

D Dhanak; L T Christmann; M G Darcy; R M Keenan; S D Knight; J Lee; L H Ridgers; H M Sarau; D H Shah; J R White; L Zhang

doi:10.1016/s0960-894x(01)00249-9

Discovery of potent and selective phenylalanine derived CCR3 receptor antagonists. Part 2

Bioorg Med Chem Lett. 2001 Jun 4;11(11):1445-50. doi: 10.1016/s0960-894x(01)00249-9.

Authors

D Dhanak¹, L T Christmann, M G Darcy, R M Keenan, S D Knight, J Lee, L H Ridgers, H M Sarau, D H Shah, J R White, L Zhang

Affiliation

¹ SmithKline Beecham Pharmaceuticals, 1250 South Collegeville Road, PO Box 5089, Collegeville, PA 19426-0989, USA. dhanak-1@sbphrd.com

PMID: 11378374
DOI: 10.1016/s0960-894x(01)00249-9

Abstract

Highly potent CCR3 antagonists have been developed from a previously reported series of phenylalanine ester-based leads. Solution-phase, parallel synthesis optimization was utilized to identify highly potent, functional CCR3 antagonists.

MeSH terms

Humans
Phenylalanine / chemical synthesis
Phenylalanine / chemistry
Phenylalanine / pharmacology*
Receptors, CCR3
Receptors, Chemokine / antagonists & inhibitors*
Receptors, Chemokine / metabolism
Structure-Activity Relationship

Substances

CCR3 protein, human
Receptors, CCR3
Receptors, Chemokine
Phenylalanine